Repligen Corporation is seeing a boost in its stock price, reflecting investor optimism.
Repligen Corporation (NASDAQ:RGEN) is up today, with shares increasing by 1.65% to close at CA$184.69. This rise comes as the company navigates the complexities of the bioprocessing sector, demonstrating its resilience amid industry challenges.
Investor takeaway: Investors are encouraged by Repligen's recent performance and strategic acquisitions, which position the company well in the bioprocessing market.
Advertisement
Repligen Corporation
RGEN.US
RGEN.US
Repligen Corporation
WealthAwesomeMarket cap
$10.00B
P/E
264.5x
52W high
$198.87
52W low
$100.99
1W change
-7.04%
Beta
1.05
Analyst Price Targets
Based on 19 analysts covering RGEN · as of Oct 1, 2026
Wall Street analysts forecast RGEN stock price to rise 7.0% over the next 12 months.
Consensus
Buy4.26 / 5.00
Avg. Target
C$189.70
+7.0% Upside
Previously C$189.48 on Sep 21, 2026
Current Price
C$177.23
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RGEN's historical volatility
30-Day Vol
42.2%
Annualized
90-Day Vol
49.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$211.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$188.10 | C$162.59 – C$217.61 |
| 60 trading days | C$199.64 | C$162.45 – C$245.33 |
| 90 trading days | C$211.88 | C$164.61 – C$272.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.65% Increase in Stock Price
Repligen's stock has gained 1.65%, showing positive investor sentiment in a competitive healthcare landscape.
Bull case
Repligen's strategic acquisitions have significantly expanded its bioprocessing portfolio, establishing it as a key player in the industry. The company's recent revenue growth of 11.9% year-on-year indicates strong demand for its specialized technologies, essential for biological drug manufacturing.
Bear case
Despite the positive revenue growth, Repligen's adjusted operating margin has declined, and earnings per share have dropped over the last five years. Investors should be cautious, as the company's profitability metrics reveal underlying challenges that could affect future performance.
Strong Revenue Growth
Advertisement
Repligen reported a revenue increase of 11.9% year-on-year, totaling $204.1 million. This performance exceeded analysts' expectations, showcasing the company's ability to meet the rising demand for bioprocessing technologies.
Strategic Acquisitions
Since 2012, Repligen has made over 13 strategic acquisitions, building a comprehensive portfolio that strengthens its market position. These acquisitions have enabled the company to innovate and enhance the efficiency of biological drug manufacturing processes.
Challenges Ahead
Even with the positive stock movement, Repligen faces challenges, including a decline in its adjusted operating margin and a decrease in earnings per share over the past five years. Investors should stay alert to these factors as they evaluate the company's long-term prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
